$0.6409
-0.18-21.61%
Last update: Nov 10, 7:55 PM
Coherus Oncology Inc
CHRSNASDAQ
Coherus Oncology fell 35.1% from $1.26 to $0.82, behind the S&P 500's +10.0%. Its worst day was Oct 29 (−22.6%), and its low came Nov 5 at $0.75.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Coherus Oncology closed at its highest level of the year, 99.2% above where the year started.
+10.1% · S&P 500 +0.4%
In addition, Coherus intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares offered in the Offering, at the public offering price per
Story events cover the past 12 months · Times ET
−19.9% · S&P 500 +0.1%
EPS of $-0.34 beat the $-0.34 estimate on $12.7M revenue (est. $13.7M).
+1.0% · S&P 500 −0.2%
EPS of $-0.25 beat the $-0.27 estimate on $12.3M revenue (est. $14.3M).
−12.3% · S&P 500 −0.2%
EPS of $-0.19 missed the $-0.12 estimate on $14.3M revenue (est. $21.6M).
−12.8% · S&P 500 −0.2%
Coherus Oncology shares rose 16.5%, while the S&P 500 fell 0.7%.
+16.5% · S&P 500 −0.7%
Coherus Oncology shares fell 22.6%, while the S&P 500 fell 0.4%.
−22.6%, the year's worst day · S&P 500 −0.4%
Where it ended: a close of $0.82 on Nov 9, 2026. Up next: Q4 2026 earnings on Mar 8, 2027 (EPS est. $-0.22, revenue est. $16.3M).
Nothing in the past 12 months.
All CHRS dividend historyReplay the year: the line draws itself and stops at each of the 7 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CHRS and SPY from Benzinga historical bars. Not investment advice.
